Synthesizing oligonucleotides often leads to the production of impurities that can be detrimental to downstream applications. These impurities are typically shorter, truncated versions of the full-length oligonucleotide. To ensure high-quality results, the solid phase synthesis and chromatographic purification processes must be carefully optimized and precisely controlled to minimize the presence of truncated side-products, leaving the oligonucleotide in a highly pure form. Biotage recognizes the need for continuous optimization of our synthesis and purification processes to ensure that our oligonucleotides are of the highest quality. This technical note compares a Biotage
oligonucleotide to the same sequence supplied by another vendor.
Literature number: PPS701